FIU Scientists Develop Sugar-Coated Shield to Boost CAR-T Cell Longevity and Efficacy
Event summary
- FIU researchers created a glycoengineered 'sugar-coated' shield for CAR-T cells, doubling their survival and efficacy in lab tests.
- The shield protects CAR-T cells from galectin-3, a protein that weakens immune cells in tumor environments.
- Tests in mice with lymphoma showed significantly smaller tumors and improved CAR-T cell performance.
- The breakthrough could extend CAR-T therapy's effectiveness to solid tumors, currently difficult to treat.
The big picture
CAR-T therapy has revolutionized blood cancer treatment but faces limitations in survival and efficacy. FIU's glycoengineering breakthrough addresses these challenges by enhancing cell resilience, potentially unlocking new applications in harder-to-treat cancers. The discovery aligns with broader industry efforts to overcome tumor immune evasion, a critical barrier in oncology.
What we're watching
- Clinical Translation
- How quickly the glycoengineered CAR-T cells advance from lab success to human trials.
- Therapeutic Expansion
- Whether the shield technology can be adapted to treat solid tumors, expanding CAR-T's reach.
- Industry Collaboration
- The pace at which biotech firms partner with FIU to commercialize the enhanced CAR-T cells.
Related topics